BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 16213482)

  • 1. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
    Senn C; Hangartner C; Moes S; Guerini D; Hofbauer KG
    Eur J Pharmacol; 2005 Oct; 522(1-3):30-7. PubMed ID: 16213482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo.
    Griesenbach U; Kitson C; Escudero Garcia S; Farley R; Singh C; Somerton L; Painter H; Smith RL; Gill DR; Hyde SC; Chow YH; Hu J; Gray M; Edbrooke M; Ogilvie V; MacGregor G; Scheule RK; Cheng SH; Caplen NJ; Alton EW
    Respir Res; 2006 Feb; 7(1):26. PubMed ID: 16480492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring RNA interference as a therapeutic strategy for renal disease.
    Takabatake Y; Isaka Y; Mizui M; Kawachi H; Shimizu F; Ito T; Hori M; Imai E
    Gene Ther; 2005 Jun; 12(12):965-73. PubMed ID: 15729369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of alpha2A-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthood.
    Shishkina GT; Kalinina TS; Dygalo NN
    Neuroscience; 2004; 129(3):521-8. PubMed ID: 15541874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
    Fattal E; Bochot A
    Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific knock-down of GAD67 in the striatum using naked small interfering RNAs.
    Manrique C; Compan V; Rosselet C; Duflo SG
    J Biotechnol; 2009 Jul; 142(3-4):185-92. PubMed ID: 19497341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small interfering RNA for experimental cancer therapy.
    Tong AW; Zhang YA; Nemunaitis J
    Curr Opin Mol Ther; 2005 Apr; 7(2):114-24. PubMed ID: 15844618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.
    Juliano RL
    Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA.
    de Martimprey H; Vauthier C; Malvy C; Couvreur P
    Eur J Pharm Biopharm; 2009 Mar; 71(3):490-504. PubMed ID: 18977435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interfering connective tissue growth factor prevents rat hepatic stellate cell activation and extracellular matrix production.
    Li G; Li D; Xie Q; Shi Y; Jiang S; Jin Y
    J Gene Med; 2008 Sep; 10(9):1039-47. PubMed ID: 18613219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular dynamics of antisense oligonucleotides and short interfering RNAs.
    Lee LK; Dunham BM; Li Z; Roth CM
    Ann N Y Acad Sci; 2006 Oct; 1082():47-51. PubMed ID: 17145924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6.
    Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM
    Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
    Toub N; Malvy C; Fattal E; Couvreur P
    Biomed Pharmacother; 2006 Nov; 60(9):607-20. PubMed ID: 16952435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of RNA interference to inhibit integrin subunit alphaV-mediated angiogenesis.
    Graef T; Steidl U; Nedbal W; Rohr U; Fenk R; Haas R; Kronenwett R
    Angiogenesis; 2005; 8(4):361-72. PubMed ID: 16400518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids.
    Zhou K; He H; Wu Y; Duan M
    J Biotechnol; 2008 Jun; 135(2):140-4. PubMed ID: 18456361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.
    Elmén J; Thonberg H; Ljungberg K; Frieden M; Westergaard M; Xu Y; Wahren B; Liang Z; Ørum H; Koch T; Wahlestedt C
    Nucleic Acids Res; 2005; 33(1):439-47. PubMed ID: 15653644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD; Huang L
    Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
    Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.